Chronic active antibody-mediated rejection (caAMR) is a common cause of allograft loss after transplantation, with no approved therapies. Clazakizumab, a monoclonal antibody that targets the inflammatory cytokine interleukin-6 (IL-6), stabilized kidney transplant recipients' kidney function in a phase 2 trial.
Phase 3 trial assesses clazakizumab in kidney transplant recipients with caAMR
- Thread starter Educator
- Start date